John Hood

Prior to Endeavor, Dr. Hood was the co-founder and CEO of Impact Biomedicines, which was acquired by Celgene Corporation for $7 billion in 2018. Prior to Impact, he was the Co-founder and Chief Scientific Officer of Samumed LLC., a pharmaceutical company focused on advancing regenerative medicine and oncology therapies. Prior to that, Dr. Hood was Director of Research and co-inventor of fedratinib at TargeGen (subsequently acquired by Sanofi S.A.) where he led a team identifying small molecule kinase inhibitors for the treatment of eye diseases and cancer. He is an inventor on 100+ patents and author on 50+ scientific articles. Dr. Hood obtained a Ph.D. in Medical Physiology and B.S. in Biochemistry from Texas A&M University.